Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.74 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.68 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.63 |
| ▸ | MMP3 | P08254 | 2/20 | 0.63 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.63 |
| ▸ | MMP13 | P45452 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18837956 | 1.00 | ADAMTS5 (0.74) | ADAMTS5PTPN12PTPN22KMT2AAKR1B1 | |
| SCHEMBL17319258 | 0.90 | PTPN12 (0.64) | ADAMTS5PTPN12PTPN22KMT2AAKR1B1 | |
| SCHEMBL12008490 | 0.88 | CISD1 (0.70) | ADAMTS5KMT2AAKR1B1PTPN1MEN1 | |
| SCHEMBL20837899 | 0.86 | KMT2A (0.71) | ADAMTS5PTPN12PTPN22KMT2AAKR1B1 | |
| SCHEMBL12008731 | 0.86 | FFAR1 (0.71) | ADAMTS5KMT2AMEN1POLB | |
| SCHEMBL10492163 | 0.86 | PTPN12 (0.77) | PTPN12PTPN22KMT2AAKR1B1MMP3 | |
| SCHEMBL10492165 | 0.86 | PTPN12 (0.77) | PTPN12PTPN22KMT2AAKR1B1MMP3 | |
| SCHEMBL10492255 | 0.85 | AKR1B1 (0.72) | ADAMTS5PTPN12PTPN22KMT2AAKR1B1 | |
| SCHEMBL10492260 | 0.85 | AKR1B1 (0.72) | ADAMTS5PTPN12PTPN22KMT2AAKR1B1 | |
| SCHEMBL14652604 | 0.85 | PTPN12 (0.67) | ADAMTS5PTPN12PTPN22KMT2AAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3374027-B1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | UNIV COLUMBIA (US) | 2021-06-23 | — | — | EP | claimed |
| US-20190231747-A1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2019-08-01 | — | — | US | claimed |
| EP-3374027-B1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | UNIV COLUMBIA (US) | 2021-06-23 | — | — | EP | disclosed |
| US-10925857-B2 | Rational drug design targeting resistant gram-negative bacterial infections to polymyxin-class antibiotics | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190231747-A1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2019-08-01 | — | — | US | disclosed |
| EP-3374027-A1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | The Trustees of Columbia University in the City of New York (US) | 2018-09-19 | — | — | EP | disclosed |
| WO-2017083859-A1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190231747-A1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | APRT, NMT2, NMT1 | ADAMTS5 2536/4885PTPN12 2586/4885PTPN22 2245/4885 |
| US-10925857-B2 | Rational drug design targeting resistant gram-negative bacterial infections to polymyxin-class antibiotics | APRT, NMT2, NMT1 | ADAMTS5 2536/4885PTPN12 2586/4885PTPN22 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.